Diffuse Large B-Cell Lymphoma Activated B-Cell Type

specific

A biologic subset of diffuse large B-cell lymphomas with a unique molecular signature or expression profile. It represents approximately 30% of diffuse large B-cell lymphomas, and is characterized by the expression of CD44, PKCbeta1, Cyclin D2, BCL-2, and IRF4/MUM1 genes. Morphologically, these lymphomas are either centroblastic or immunoblastic (ratio 2:1). Patients with this type of diffuse large B-cell lymphoma are reported to have a less favorable outcome compared to those with a germinal

36

Centers

14

Active Trials

Cancer Funding

Top Centers for Diffuse Large B-Cell Lymphoma Activated B-Cell Type(36)

Ranked by research excellence score (trials · grants · publications). Methodology →

#CenterScore
1
NCI Comprehensive
Active Research Program
65.1
2
NCI Comprehensive
Active Research Program
65.1
3
NCI Comprehensive
Active Research Program
65.1
4
NCI Comprehensive
Active Research Program
65.1
5
NCI Comprehensive
Active Research Program
65.1
6
NCI Comprehensive
Active Research Program
65.1
7
NCI Comprehensive
Active Research Program
65.1
8
NCI Comprehensive
Active Research Program
65.1
9
NCI Comprehensive
Active Research Program
65.1
10
NCI Comprehensive
Active Research Program
65.1
11
Active Research Program
65.1
12
Active Research Program
65.1
13
Active Research Program
65.1
14
Active Research Program
65.1
15
NCI Comprehensive
42.6
16
NCI Comprehensive
42.6
17
NCI Comprehensive
42.6
18
NCI Comprehensive
42.6
19
NCI Comprehensive
42.6
2042.6
21
NCI Comprehensive
42.6
22
NCI Comprehensive
42.6
23
NCI Comprehensive
42.6
24
NCI Comprehensive
42.6
2542.6
26
Cedars-Sinai CancerLos Angeles, CA
42.6
27
NCI Comprehensive
42.6
2842.6
2942.6
30
Rutgers Cancer InstituteNew Brunswick, NJ
NCI Comprehensive
42.6
3142.6
3242.6
3342.6
3442.6
3542.6
3642.6

Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →